The Distribution, Drug Susceptibility, and Dynamic Trends of Pseudomonas aeruginosa Infection in a Tertiary Hospital in China During 2016‒2022

References

• Ong DS, Jongerden IP, Buiting AG, et al. Antibiotic exposure and resistance development in Pseudomonas aeruginosa and Enterobacter species in intensive care units. Crit Care Med. 2011;11:2458–2463. doi:10.1097/CCM.0b013e318225756d
   Google Scholar
• Sadikot RT, Blackwell TS, Christman JW, et al. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med. 2005;171(11):1209–1223. doi:10.1164/rccm.200408-1044SO
   PubMed Web of Science ®Google Scholar
• Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370:1198–1208. doi:10.1056/NEJMoa1306801
   PubMed Web of Science ®Google Scholar
• Walter J, Haller S, Quinten C, et al. Healthcare-associated pneumonia in acute care hospitals in European Union/European Economic Area countries: an analysis of data from a point prevalence survey, 2011 to 2012. Euro Surveill. 2018;23:1700843. doi:10.2807/1560-7917.ES.2018.23.32.1700843
   PubMedGoogle Scholar
• Waters CM, Goldberg JB. Pseudomonas aeruginosa in cystic fibrosis: a chronic cheater. Proc Natl Acad Sci U S A. 2019;116:6525–6527. doi:10.1073/pnas.1902734116
   PubMed Web of Science ®Google Scholar
• Malhotra S, Hayes D, Wozniak DJ. Cystic fibrosis and Pseudomonas aeruginosa: the host-microbe interface. Clin Microbiol Rev. 2019;32:e00138–e00118. doi:10.1128/CMR.00138-18
   PubMed Web of Science ®Google Scholar
• Carmeli Y, Troillet N, Eliopoulos GM, et al. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999;43:1379–1382.
   PubMed Web of Science ®Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P aeruginosa). Clin Infect Dis. 2021;72:e169–e183. doi:10.1093/cid/ciaa1478
   PubMedGoogle Scholar
• Thöming JG, Häussler S. Pseudomonas aeruginosa is more tolerant under biofilm than under planktonic growth conditions: a multi-isolate survey. Front Cell Infect Microbiol. 2022;12:851784. doi:10.3389/fcimb.2022.851784
   PubMedGoogle Scholar
• Obritsch MD, Fish DN, MacLaren R, et al. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother. 2004;12:4606–4610. doi:10.1128/AAC.48.12.4606-4610.2004
   Google Scholar
• Obritsch MD, Fish DN, MacLaren R, et al. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy. 2005;10(10):1353–1364. doi:10.1592/phco.2005.25.10.1353
   Google Scholar
• Giamarellos-Bourboulis EJ, Papadimitriou E, Galanakis N, et al. Multidrug resistance to antimicrobials as a predominant factor influencing patient survival. Int J Antimicrob Agents. 2006;6:476–481. doi:10.1016/j.ijantimicag.2005.12.013
   Google Scholar
• Li Y, Lv Y, Zheng B. Ministry of Health National Antimicrobial Resistance Investigation Net annual report of 2011: surveillance of antimicrobial resistance in nonfermenting gram-negative bacteria in China. Chin J Clin Pharmacol. 2012;12:883–887.
   Google Scholar
• Cui J, Li M, Cui J, et al. The proportion, species distribution and dynamic trends of bloodstream infection cases in a tertiary hospital in China, 2010–2019. Infection. 2022;50(1):121–130. doi:10.1007/s15010-021-01649-y
   PubMed Web of Science ®Google Scholar
• Lila G, Mulliqi-Osmani G, Bajrami R, et al. The prevalence and resistance patterns of Pseudomonas aeruginosa in a tertiary care hospital in Kosovo. Infez Med. 2017;25(1):21–26.
   PubMedGoogle Scholar
• Wan YK, Sang W, Chen B, et al. Distribution and drug resistance of pathogens at hematology department of Jiangsu Province from 2014 to 2015: results from a multicenter, retrospective study. Zhonghua Xue Ye Xue Za Zhi. 2017;38:602–606. doi:10.3760/cma.j.issn.0253-2727.2017.07.010
   PubMedGoogle Scholar
• Gales AC, Torres PL, Vilarinho DS, et al. Carbapenem-resistant Pseudomonas aeruginosa outbreak in an intensive care unit of a teaching hospital. Braz J Infect Dis. 2004;8(4):267–271. doi:10.1590/S1413-86702004000400001
   PubMedGoogle Scholar
• Savas L, Duran N, Savas N, et al. The prevalence and resistance patterns of pseudomonas aeruginosa in intensive care units in a University Hospital. Turk J Med Sci. 2005;35:317–322.
   Google Scholar
• Wunderink R, Mendoza D. Epidemiology of Pseudomonas aeruginosa in the intensive care unit. In: Rello J, Kollef M, Diaz E, Rodriguez A, editors. Infectious Diseases in Critical Care. Berlin Heidelberg: Springer; 2007:218–225.
   Google Scholar
• Chalmers JD, Smith MP, McHugh BJ, et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012;186(7):657–665. doi:10.1164/rccm.201203-0487OC
   PubMed Web of Science ®Google Scholar
• Guan WJ, Gao YH, Xu G, et al. Sputum matrix metalloproteinase-8 and −9 and tissue inhibitor of metalloproteinase-1 in bronchiectasis: clinical correlates and prognostic implications. Respirology. 2015;20:1073–1081. doi:10.1111/resp.12582
   PubMedGoogle Scholar
• Angrill J, Agusti C, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax. 2002;57:15–19. doi:10.1136/thorax.57.1.15
   PubMed Web of Science ®Google Scholar
• Guan WJ, Gao YH, Xu G, et al. Sputum bacteriology in steady-state bronchiectasis in Guangzhou, China. Int J Tubercul Lung Dis. 2015;19(5):610–619. doi:10.5588/ijtld.14.0613
   PubMed Web of Science ®Google Scholar
• Guan WJ, Gao YH, Xu G, et al. Effect of airway Pseudomonas aeruginosa isolation and infection on steady-state bronchiectasis in Guangzhou, China. J Thorac Dis. 2015;7:625–636. doi:10.3978/j.issn.2072-1439.2015.04.04
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Annual epidemiological reports; 2014. Available from: http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-annual-epidemiological-report.pdf. Accessed August 20, 2022.
   Google Scholar
• Kos VN, Déraspe M, McLaughlin RE, et al. The resistome of Pseudomonas aeruginosa in relationship to phenotypic susceptibility. Antimicrob Agents Chemother. 2015;59:427–436. doi:10.1128/AAC.03954-14
   PubMed Web of Science ®Google Scholar
• Rao YB, Ren ZX, Zhong JJ, et al. Risk factors for imipenem-resistant Pseudomonas aeruginosa in neonatal intensive care units in south China. J Hosp Infect. 2018;98:305–308. doi:10.1016/j.jhin.2017.12.016
   PubMed Web of Science ®Google Scholar
• Gao YH, Guan WJ, Zhu YN, et al. Antibiotic-resistant Pseudomonas aeruginosa infection in patients with bronchiectasis: prevalence, risk factors and prognostic implications</em>. Int J Chron Obstruct Pulmon Dis. 2018;13:237–246. doi:10.2147/COPD.S150250
   PubMed Web of Science ®Google Scholar
• Hu YY, Cao JM, Yang Q, et al. Risk factors for carbapenem-resistant Pseudomonas aeruginosa, Zhejiang Province, China. Emerg Infect Dis. 2019;25:1861–1867. doi:10.3201/eid2510.181699
   PubMed Web of Science ®Google Scholar
• Odoi H, Boamah VE, Duah Boakye Y, et al. Sensitivity patterns, plasmid profiles and clonal relatedness of multi-drug resistant Pseudomonas aeruginosa isolated from the Ashanti Region, Ghana. Environ Health Insights. 2022;16:11786302221078117. doi:10.1177/11786302221078117
   Web of Science ®Google Scholar